Bio-Techne Corporation (TECH)
Market Cap | 11.61B |
Revenue (ttm) | 1.12B |
Net Income (ttm) | 261.82M |
Shares Out | 157.28M |
EPS (ttm) | 1.61 |
PE Ratio | 45.66 |
Forward PE | 42.19 |
Dividend | $0.32 (0.43%) |
Ex-Dividend Date | Feb 10, 2023 |
Volume | 603,725 |
Open | 73.05 |
Previous Close | 72.56 |
Day's Range | 72.66 - 74.04 |
52-Week Range | 68.00 - 113.81 |
Beta | 1.24 |
Analysts | Buy |
Price Target | 103.14 (+39.66%) |
Earnings Date | May 3, 2023 |
About TECH
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cel... [Read more]
Financial Performance
In 2022, Bio-Techne's revenue was $1.11 billion, an increase of 18.75% compared to the previous year's $931.03 million. Earnings were $272.05 million, an increase of 93.75%.
Financial StatementsAnalyst Forecast
According to 20 analysts, the average rating for TECH stock is "Buy." The 12-month stock price forecast is $103.14, which is an increase of 39.66% from the latest price.
News

BIO-TECHNE ANNOUNCES COMPLETION OF CELL AND GENE THERAPY CATAPULT PROCESS ANALYTICAL TECHNOLOGY (PAT) CONSORTIUM
MINNEAPOLIS , March 15, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it has completed its participation in the Cell and Gene Therapy Catapult Process Analytical Technolog...

BIO-TECHNE TO PRESENT AT THE BARCLAYS GLOBAL HEALTHCARE CONFERENCE
MINNEAPOLIS , March 10, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel, Executive Vice President and Chief Financial Officer, will present at the Barclays G...

BIO-TECHNE ANNOUNCES INVESTMENT IN WILSON WOLF
MINNEAPOLIS , March 1, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced Wilson Wolf Manufacturing has met the trailing 12-month earnings before interest, taxes, depreciation, ...

BIO-TECHNE TO PRESENT AT THE COWEN 43rd ANNUAL HEALTH CARE CONFERENCE
MINNEAPOLIS , Feb. 28, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Cowen 43rd Annual Healt...

ExoDx PROSTATE TEST GRANTED EXPANDED COVERAGE BY MEDICARE
Medicare contractor National Government Services finalizes local coverage determination for biomarker testing related to prostate cancer to include repeat biopsies and yearly testing MINNEAPOLIS , Feb...

BIO-TECHNE TO PRESENT AT THE CITI 2023 HEALTHCARE SERVICES, MEDTECH, TOOLS & HCIT CONFERENCE
MINNEAPOLIS , Feb. 22, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel, Executive Vice President and Chief Financial Officer, will present at the Citi 2023 H...

BIO-TECHNE AND CELL SIGNALING TECHNOLOGY ANNOUNCE PARTNERSHIP TO VALIDATE SIMPLE WESTERN ANTIBODIES
MINNEAPOLIS , Feb. 14, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) and Cell Signaling Technology ( CST) announced today the addition of Simple Western™ validation to CST antibodies. Th...

Techne (TECH) Q2 Earnings and Revenues Miss Estimates
Techne (TECH) delivered earnings and revenue surprises of -4.08% and 6.34%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

BIO-TECHNE DECLARES DIVIDEND
MINNEAPOLIS , Feb. 2, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended December 3...

BIO-TECHNE RELEASES SECOND QUARTER FISCAL 2023 RESULTS
MINNEAPOLIS , Feb. 2, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the second quarter ended December 31, 2022. Second Quarter FY2023 Highlights S...

BIO-TECHNE ANNOUNCES RETIREMENT, APPOINTMENT OF GENERAL COUNSEL
MINNEAPOLIS , Jan. 31, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced Shane Bohnen has been appointed Senior Vice President, General Counsel effective March 3, 2023. Mr. B...

5 Cheapest Health Care Stocks You Should Think About
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Techne (TECH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Techne (TECH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BIO-TECHNE LAUNCHES THE MauriceFlex™ SYSTEM, ADDING cIEF FRACTIONATION CAPABILITY TO THE GOLD STANDARD MAURICE ASSAYS
MINNEAPOLIS , Jan. 26, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced the launch of its ProteinSimple-branded MauriceFlex™ during the WCBP conference in Washington D.C. Mau...

5 Health Care Stocks That Are Diving - And May Rally
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

BIO-TECHNE TO HOST CONFERENCE CALL ON FEBRUARY 2, 2023, TO ANNOUNCE SECOND QUARTER 2023 FINANCIAL RESULTS
MINNEAPOLIS, Jan. 17, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Thursday, February 2, 2023, at 8:00 a.m. CST...

REGN or TECH: Which Is the Better Value Stock Right Now?
REGN vs. TECH: Which Stock Is the Better Value Option?

BIO-TECHNE LAUNCHES RNASCOPE PLUS ASSAY TO ADVANCE GENE THERAPY DEVELOPMENT
An integrated assay using proprietary RNAscope ™ and miRNAscope ™ technologies to measure the biodistribution and function of novel gene therapies and endogenous regulatory RNAs. MINNEAPOLIS , Jan. 10...

GSK or TECH: Which Is the Better Value Stock Right Now?
GSK vs. TECH: Which Stock Is the Better Value Option?

BIO-TECHNE TO PRESENT AT THE 41st ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
MINNEAPOLIS , Dec. 21, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan...

Our 7 Top Biotech Stock Picks for 2023
If there's a silver lining regarding the coronavirus pandemic, it's that it demonstrated the importance of the top biotech stock picks for 2023. While medical innovations may seem frustratingly slow, ...

BIIB vs. TECH: Which Stock Is the Better Value Option?
BIIB vs. TECH: Which Stock Is the Better Value Option?

BIO-TECHNE RELEASES MITOBRILLIANT™ FLUORESCENT DYES, PROVIDING A NEXT-GENERATION TOOL FOR IMAGING MITOCHONDRIA IN LIVE AND FIXED CELLS
MINNEAPOLIS, Dec. 5, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced the introduction of MitoBrilliant™ probes. These novel probes enable the fluorescent labeling and track...

Bio-Techne and Oxford Nanopore Technologies partner to bring innovative reproductive health and carrier screening solutions to the market
New collaboration will develop assays that offer a streamlined workflow for analysing even the most challenging genes. MINNEAPOLIS , Dec. 1, 2022 /PRNewswire/ -- Asuragen, a Bio-Techne brand (NASDAQ: ...

BIO-TECHNE TO PRESENT AT THE FIFTH ANNUAL EVERCORE ISI HealthCONx CONFERENCE
MINNEAPOLIS , Nov. 28, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Fifth Annual Evercore I...